Back to top

Analyst Blog

On May 23, 2012, testing instrument maker-Mesa Laboratories Inc. reported its fourth quarter fiscal 2012 adjusted (excluding one-time expenses such as acquisition-related intangible amortizations) earnings of 76 cents per share, up 7% from the year-ago earnings of 71 cents. The earnings per share increased 20.6% on a sequential basis.

Profit rose 1% to $2.2 million (62 cents a share) from $2.18 million of the prior year quarter. The profit includes an unfavorable impact of a non-cash expense of $0.35 million for impairment of acquisitions during the fourth quarter.

For fiscal 2012, the adjusted earnings per share stood at $2.63, up 26.4% from the prior fiscal year. Profit rose 28% to $7.9 million ($2.29 per diluted share) for fiscal 2012.

Revenues

Revenues increased by 6% year over year to $10.5 million, buoyed by robust sales of its three largest product lines. The company crossed the $10 million revenue mark for the very first time.  For the fiscal 2012, revenues improved 16% year over year to $38 million.

Segment Analysis

The company has two major business segments — Instruments and Biological Indicators. The Instruments segment revenue increased 5% and 10% during fourth quarter and full year, respectively.  

The Biological Indicator segment revenue increased 6% and 21% during fourth quarter and full year, respectively. The organic growth of the products boosted segment revenue for the reported quarter and for the year. The acquisition of Apex in December 2010 accounted for the robust sales growth of the segment during fiscal 2012.

The organic growth rate for three largest product lines of Mesa Laboratories — Medical, Biological Indicators and DataTrace — exceeded 10% for fiscal 2012. It reflects optimum use of internal resources and enhanced sales.

Margins

Gross margin for the fourth quarter was 61.7% compared with 62.2% in the prior year quarter.  Operating margin declined to 31.7% from 33.4% a year ago. 

For fiscal 2012, gross margin of 61.9% increased slightly from 59.6% in the previous year. Operating margin increased to 32.9% from 30.1% a year ago.

Financial Position

Mesa ended fiscal 2012 with a healthy balance sheet. Cash and cash equivalents more than doubled from fiscal 2011 to $7.2 million.

Management expects healthy revenue growth for fiscal 2013 based on synergies from the acquisition of Bios International Corporation. The acquisition of the flow calibrator business of Bios will enhance the instrumentation product portfolio of Mesa.

Like Mesa, Bios also manufactures high margin products. The high profit margins of Bios products coupled with its strong market presence will benefit the company considerably. The acquisition will also allow Mesa to focus on developing quality control products for regulated industries. Mesa therefore expects the acquisition to be accretive to its net income and earnings per share.

Mesa, which competes with Cantel Medical Corp. , Danaher Corp. (DHR - Analyst Report) andThermo Fisher Scientific, Inc (TMO - Analyst Report), has a proven track record of healthy growth boosted by new product development and acquisitions. With the acquisition of Bios and a strong product pipeline, management expects the company to be well positioned for long-term growth.

The stock currently retains Zacks #1 Rank, which translates into a short-term Strong Buy rating.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%